Enovis (NYSE:ENOV) Stock Price Down 7.9% – What’s Next?

Enovis Corporation (NYSE:ENOV)’s share price traded down 7.9% during mid-day trading on Tuesday . The stock traded as low as $20.11 and last traded at $20.2730. 87,471 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 1,058,294 shares. The stock had previously closed at $22.02.

Analyst Ratings Changes

Several brokerages have weighed in on ENOV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Sunday. Wells Fargo & Company reduced their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Down 11.5%

The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The company has a market capitalization of $1.12 billion, a PE ratio of -0.97 and a beta of 1.38. The company’s 50 day moving average is $23.51 and its two-hundred day moving average is $24.00.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts anticipate that Enovis Corporation will post 3.65 earnings per share for the current year.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders bought 4,200 shares of company stock valued at $92,084 in the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC increased its position in Enovis by 12.5% in the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. Finally, Amundi increased its holdings in shares of Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after buying an additional 9,762 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.